Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.

Vahle JL, Byrd RA, Blackbourne JL, Martin JA, Sorden SD, Ryan T, Pienkowski T, Wijsman JA, Smith HW, Rosol TJ

Endocrinology10 Apr 2015Cited by 9 (Europe PMC)

PMID25860028DOI10.1210/en.2014-1717PepBankPUB-25860028

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not increase basal serum calcitonin in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not raise basal calcitonin compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBasal serum calcitonin
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
2 context sentences(design, population, supporting numbers)
Summary · context
Basal and calcium gluconate-stimulated serum calcitonin concentrations were obtained at 3, 6, 9, and 12 months.
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002801
02AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not increase calcium-stimulated serum calcitonin in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not raise stimulated calcitonin compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeStimulated serum calcitonin
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
2 context sentences(design, population, supporting numbers)
Summary · context
Basal and calcium gluconate-stimulated serum calcitonin concentrations were obtained at 3, 6, 9, and 12 months.
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002802
03AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not affect thyroid weight in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not change thyroid weight compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeThyroid weight
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002803
04AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not affect thyroid histology in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not change thyroid tissue structure compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeThyroid histology
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002804
05AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not affect thyroid C-cell proliferation in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not change thyroid C-cell multiplication compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeC-cell proliferation
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002805
06AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not affect absolute thyroid C-cell volume in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not change absolute thyroid C-cell volume compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAbsolute C-cell volume
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002806
07AnimalAnimal study (in vivo)Safety outcome
Dulaglutide did not affect relative thyroid C-cell volume in male cynomolgus monkeys versus vehicle.
In plain wordsIn monkeys, dulaglutide did not change relative thyroid C-cell volume compared with vehicle.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeRelative C-cell volume
Study
cynomolgus monkeyn = 40
Male cynomolgus monkeys
Comparator
Vehicle control
Outcome group
Adverse events · Endocrine and hormones
Studied dose
8.15 mg/kg twice weekly · subcutaneous · 52 weeksAs given in this study (cynomolgus monkey).
Source sentences
Summary
Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks.
Report a problemFND-2586002807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.